Skip to content

LEFEVRE PHARMA

Active
Private limited companyfounded 2010active for 15 yearsRoute de Gosselies(WAN) 331, 6220 Fleurus, BelgiumKBO/BCE: BE 0831.780.443

Acts, filings and financial milestones

Deadline for the 2026 accounts: 31-07-2027
2026
03-06
NBB filing Annual accounts 2025 filedPDF
full format · 58 days before the deadline
2025
05-06
NBB filing Annual accounts 2024 filedPDF
micro format · 56 days before the deadline
2024
23-08
NBB filing Annual accounts 2023 filedPDF
micro format · 23 days late
2023
13-12
Gazette deed Change of role: LEFEVRE Marie-Odile, from manager to director
“La participation à tous services paramédicaux, au siège de la société ou chez les patients ou en tout autre…” (deed in French) · Registered office clause: route de Gosselies 331, 6220 Wangenies5 points ▸
  • General meeting, 28-11-2023
  • Purpose change, “La participation à tous services paramédicaux, au siège de la société ou chez les patients ou en tout autre lieu, tels que les prestations de services…” (deed in French)
  • Director resignation, LEFEVRE Marie-Odile (manager)
  • Director appointment, LEFEVRE Marie-Odile (director (not named in the articles))
  • Registered office clause, route de Gosselies 331, 6220 Wangenies
  • The act holds 5 more points.

Open the act in the Belgian Official Gazette

08-08
NBB filing Annual accounts 2022 filedPDF
full format · 8 days late
03-07
Gazette deed Registered office moved from Fleurus to Wangenies
New seat: route de Gosselies, 331 à 6220 Wangenies · Previous seat: Rue Jules Destrée(WAN) 89 - 6220 Fleurus - Belgique · Director in office: Marie-Odile Lefevre3 points ▸
  • General meeting, 13-04-2023
  • Registered-office move, route de Gosselies, 331 à 6220 Wangenies
  • Director in office, Marie-Odile Lefevre (director)

Open the act in the Belgian Official Gazette

2022
31-12
Financial Equity above €200,000equity €221,671 ▲31.8%
After 2 profitable years in a row, equity reaches €221,671.
31-03
NBB filing Annual accounts 2021 filedPDF
full format · 122 days before the deadline
2021
31-12
Financial Back to profitnet €64,806
The net result is €64,806, after one loss-making year.
31-12
Financial Equity above €150,000equity €168,224 ▲38.5%
Equity rises from €121,418 to €168,224.
23-08
NBB filing Annual accounts 2020 filedPDF
full format · 23 days late
2020
31-12
Financial Weakest financial yearnet -€18,083
The net result drops to -€18,083, the lowest from 2018 to 2025. It recovers the following year.
Show earlier events
25-08
NBB filing Annual accounts 2019 filedPDF
full format · 25 days late
2019
22-10
NBB filing Annual accounts 2018 filedPDF
full format · 83 days late
2018
30-08
NBB filing Annual accounts 2017 filedPDF
full format · 30 days late
2017
19-07
NBB filing Annual accounts 2016 filedPDF
full format · 12 days before the deadline
2010
21-12
Gazette deed IncorporationPDF
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.

Sources:Publications in the Belgian Official GazetteFilings with the National Bank

History

On 10 December 2010, LEFEVRE PHARMA was incorporated.1 In 2023 the registered office moved to Wangenies.2 Total assets went from €862,455 in 2018 to €1.5m in 2025 and headcount from 0.8 full-time equivalents in 2019 to 3 in 2025.3

  1. 1KBO register
  2. 2Belgian Official Gazette, 03-07-2023
  3. 3National Bank, annual accounts 2018, 2019 and 2025

Next steps